...
首页> 外文期刊>International Journal of Hypertension >Comparison of Effects of ACEIs and ARBs on Albuminuria and Hyperkalemia in Indonesian Hypertensive Type 2 Diabetes Mellitus Patients
【24h】

Comparison of Effects of ACEIs and ARBs on Albuminuria and Hyperkalemia in Indonesian Hypertensive Type 2 Diabetes Mellitus Patients

机译:Aceis和Arbs对印度尼西亚高血压型2型糖尿病患者的蛋白尿和高钾血症的影响比较

获取原文
           

摘要

Purpose. Due to economic consideration, Indonesia’s formulary restrictions are at odds with the treatment guidelines of the American Diabetes Association (ADA) and the Eighth Joint National Committee (JNC 8). ADA and JNC 8 equally recommend the prescription of an angiotensin-converting enzyme inhibitor (ACEI) or angiotensin II receptor blocker (ARB) for hypertensive patients with type 2 diabetes mellitus (T2DM) with overt proteinuria (urine albumin to creatinine ratio (UACR)?≥?300?mg/g creatinine). However, since 1 April 2018, Indonesian formulary restricted telmisartan and valsartan only for T2DM patients with declined renal function as shown by eGFR value. There is no compelling evidence in favor of ACEI over ARB or vice versa except for data supporting the early use of both drugs in patients with overt proteinuria. However, ARB is a choice if ACEI’s side effects, that is, coughing, occurs. Therefore, it necessitates a detailed evaluation of the effects of ACEIs and ARBs on albuminuria and their side effect, hyperkalemia, specific to Indonesian T2DM patients. Methods. This cross-sectional study involved 134 T2DM patients whose treatment was restricted to either ACEIs (n?=?57) or ARBs (n?=?77) for at least two months before the study during May–October 2018. Patients with known end-stage renal disease and those receiving dialysis were excluded. UACR and blood potassium levels were compared between the two study groups. Also, the risk factors of albuminuria and hyperkalemia were estimated using multivariate analysis. Results. T2DM patients in the ACEI and ARB groups had similar characteristics except for a higher body mass index (p=0.008), lower glomerular filtration rate (p=0.04), and a longer duration of prior treatment (p0.001) in the ARB group. This study showed no differences between the ACEI and ARB groups in the proportion of cases with albuminuria (p=0.97) and hyperkalemia (p=0.86), even after adjustment for confounders. In addition, uncontrolled diastolic blood pressure was a significant factor associated with albuminuria (OR: 4.897, 95% CI: 1.026–23.366; p=0.046), whereas a female was 70.1% less likely to develop hyperkalemia than a male (OR: 0.299, 95% CI: 0.102–0.877; p=0.028). Conclusion. This cross-sectional study demonstrated that ACEIs and ARBs have a similar effect on albuminuria and hyperkalemia in Indonesian hypertensive T2DM patients, even after correction for potentially confounding variables.
机译:目的。由于经济审议,印度尼西亚的形式限制与美国糖尿病协会(ADA)和第八届联合国家委员会(JNC 8)的治疗指南有所差不多。 ADA和JNC 8同样建议将血管紧张素转换酶抑制剂(ACEI)或血管紧张素II受体阻滞剂(ARB)用于高血压患者的血管生素抑制剂(T2DM),具有公开蛋白尿(尿白蛋白至肌酐比(UACR)? ≥300?mg / g肌酐)。但是,自2018年4月1日起,印度尼西亚尔公式仅限于T2DM患者的Telmisartan和Valsartan,如EGFR值所示。除了支持具有明显蛋白尿患者的患者早期使用两种药物的数据外,没有引人注目的证据支持ACE,反之亦然。然而,如果Acei的副作用,即咳嗽,则是一种选择。因此,它需要详细评估Aceis和ARBS对白蛋白尿和副作用,高钾血症的影响,特异于印度尼西亚T2DM患者。方法。这种横截面研究涉及134名T2DM患者,其治疗被限制在2018年5月至10月期间的研究前至少两个月的Aceis(N?= 57)或ARBS(n?=?77)。患者已知结束排除肾病和接受透析的人。在两项研究组之间比较了UACR和血钾水平。此外,使用多元分析估计白蛋白尿和高钾血症的危险因素。结果。 Acei和Arb组中的T2DM患者具有相似的特性,除了较高的体重指数(P = 0.008),较低的肾小球过滤速率(P = 0.04),以及ARB组中的早熟持续时间(P <0.001) 。该研究表明,即使在对混凝剂的调整后,Acei和Arb组在含有白蛋白尿(P = 0.97)和高钾血症(P = 0.86)的情况下的案例之间的差异也没有差异。此外,不受控制的舒张压是与白蛋白尿有关的重要因素(或:4.897,95%CI:1.026-23.366; p = 0.046),而雌性比男性显影高钾血症可能减少70.1%(或:0.299) ,95%CI:0.102-0.877; P = 0.028)。结论。这种横截面研究表明,即使在纠正潜在混淆变量之后,Aceis和Arbs对印度尼西亚高血压T2DM患者的白蛋白尿和高钾血症具有类似的效果。

著录项

相似文献

  • 外文文献
  • 中文文献
  • 专利
获取原文

客服邮箱:kefu@zhangqiaokeyan.com

京公网安备:11010802029741号 ICP备案号:京ICP备15016152号-6 六维联合信息科技 (北京) 有限公司©版权所有
  • 客服微信

  • 服务号